SINTX Strengthens Patent Portfolio to Support International Growth Across Healthcare Markets
Nov 17, 2026, 9:42 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
These IP milestones expand territorial protection for SINTX’s SiNERGY platform and, if allowances convert to granted patents and are enforceable, could enable licensing, OEM deals or product commercialization that support future revenue; the economic benefit depends on claim scope, grant completion and partner agreements.
AI summary
What happened, with direct paths to the underlying reporting
SINTX announced two issued patents and three allowed patent applications in Europe, Canada, Japan and South Korea covering silicon nitride coatings, implant manufacturing methods, antipathogenic fibrous materials, and antifungal composites.
SINTX reported two patent issuances and three patent allowances across Europe, Canada, Japan and South Korea.
The European Patent Office allowed Application No. 22212616.1 and Application No. 22873861.3 for silicon nitride coatings and manufacturing methods for implants.
Japanese Patent No. 7935430 titled “Anti-pathogenic fibrous material” was issued, covering fibrous materials containing silicon nitride for sutures, face masks and wound dressings.
Canada issued a patent from Application No. 3,163,598 and South Korea allowed Application No. 10-2022-7029227 in the antifungal composite family for dental prostheses and related applications.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event